Predicting treatment response in advanced gastric cancer using multi-omics data
Predicting Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/gastroesophageal Junction Cancer Based on the Multi-omics Information During Tumor Evolution.
Zhejiang Cancer Hospital · NCT06642857
This study is trying to see if certain biological markers in blood, saliva, and feces can help predict how well immunotherapy combined with chemotherapy works for people with advanced gastric cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Zhejiang Cancer Hospital (other) |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06642857 on ClinicalTrials.gov |
What this trial studies
This project aims to integrate multi-omics data to identify key features that correlate with the therapeutic effects of immunotherapy combined with chemotherapy in patients with advanced gastric and gastroesophageal junction cancer. The study will extract and analyze various biological samples, including blood, saliva, and feces, to screen for potential molecular markers and dominant microbiota that may predict treatment efficacy. Additionally, a multimodal predictive model will be established to optimize clinical decision-making for patients undergoing this combined treatment approach.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 75 with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior anti-tumor treatments.
Not a fit: Patients with HER2 positive tumors, those who have received previous anti-tumor treatments, or individuals with severe comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the ability to predict which patients will benefit from immunotherapy combined with chemotherapy, leading to more personalized treatment plans.
How similar studies have performed: While the approach of using multi-omics data for treatment prediction is gaining traction, this specific application in advanced gastric cancer is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria： * Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathology and with advanced or metastatic disease that cannot be resected * HER2 negative * Not received any anti-tumor treatment before. * After evaluation, the treatment plan is chemotherapy combined with immunotherapy. * Aged 18 to 75 years old, gender is not limited. * Expected survival time is greater than or equal to 3 months. Exclusion criteria： * Patients with malignant tumors other than gastric cancer or those with tumors metastasized to the stomach from other sites. * Patients who have previously received anti-tumor treatments such as surgery, radiotherapy and chemotherapy, targeted therapy or immunotherapy. * Patients with severe infections. * Those with a history of mental illness cannot cooperate with the research. * Patients with severe heart, liver, kidney and other diseases. * Pregnant or lactating patients. * HER2 positive.
Where this trial is running
Hangzhou, Zhejiang
- Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) — Hangzhou, Zhejiang, China (RECRUITING)
Study contacts
- Study coordinator: Xiangdong Cheng Cheng, PhD
- Email: Chengxd516@126.com
- Phone: +0086-0571-88128041
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Chemotherapy combined with immunotherapy, efficacy prediction